B-intervention	0	11	Venlafaxine
O	12	18	versus
B-control	19	28	clonidine
O	29	32	for
O	33	36	the
O	37	46	treatment
O	47	49	of
B-condition	50	53	hot
I-condition	54	61	flashes
O	62	64	in
O	65	71	breast
O	72	78	cancer
O	79	87	patients
O	87	88	:
O	89	90	a
O	91	97	double
O	97	98	-
O	98	103	blind
O	103	104	,
O	105	115	randomized
O	116	121	cross
O	121	122	-
O	122	126	over
O	127	132	study
O	132	133	.

O	134	140	Breast
O	141	147	cancer
O	148	156	patients
O	157	161	with
O	162	171	treatment
O	171	172	-
O	172	179	induced
O	180	189	menopause
O	190	200	experience
O	201	209	frequent
O	210	213	and
O	214	220	severe
O	221	224	hot
O	225	232	flashes
O	233	234	(
O	234	236	HF
O	236	237	)
O	237	238	.

O	239	241	We
O	242	250	compared
O	251	262	venlafaxine
O	263	266	and
O	267	276	clonidine
O	277	280	for
O	281	284	the
O	285	294	treatment
O	295	297	of
O	298	300	HF
O	301	305	with
O	306	312	regard
O	313	315	to
O	316	320	side
O	321	328	effects
O	328	329	,
O	330	338	efficacy
O	338	339	,
O	340	347	quality
O	348	350	of
O	351	355	life
O	356	359	and
O	360	366	sexual
O	367	378	functioning
O	378	379	.

O	380	382	In
O	383	384	a
O	385	391	double
O	391	392	-
O	392	397	blind
O	397	398	,
O	399	404	cross
O	404	405	-
O	405	409	over
O	410	415	study
O	415	416	,
B-total-participants	417	419	60
B-eligibility	420	426	breast
I-eligibility	427	433	cancer
I-eligibility	434	442	patients
I-eligibility	443	455	experiencing
I-eligibility	456	458	HF
O	459	463	were
O	464	474	randomized
O	475	477	to
O	478	479	8
O	480	485	weeks
O	486	497	venlafaxine
O	498	506	followed
O	507	509	by
O	510	511	2
O	512	517	weeks
O	518	522	wash
O	522	523	-
O	523	526	out
O	526	527	,
O	528	531	and
O	532	533	8
O	534	539	weeks
O	540	549	clonidine
O	550	552	or
O	553	557	vice
O	558	563	versa
O	563	564	.

O	565	567	HF
O	568	577	frequency
O	578	581	and
O	582	590	severity
O	590	591	,
O	592	596	side
O	597	604	effects
O	604	605	,
O	606	613	quality
O	614	616	of
O	617	621	life
O	622	625	and
O	626	635	sexuality
O	636	640	were
O	641	649	assessed
O	649	650	.

B-intervention-participants	651	657	Thirty
O	658	666	patients
O	667	674	started
O	675	679	with
O	680	691	venlafaxine
O	692	695	and
B-control-participants	696	698	30
O	699	703	with
O	704	713	clonidine
O	713	714	.

B-outcome	715	724	Premature
I-outcome	725	740	discontinuation
I-outcome	741	744	for
I-outcome	745	753	toxicity
O	754	762	occurred
O	763	765	in
B-iv-bin-abs	766	768	14
O	768	769	/
B-intervention-participants	769	771	59
O	772	778	during
O	779	790	venlafaxine
O	791	794	and
B-cv-bin-abs	795	796	5
O	796	797	/
B-control-participants	797	799	53
O	800	806	during
O	807	816	clonidine
O	817	818	(
O	818	819	P
O	820	821	=
O	822	823	.
O	823	826	038
O	826	827	)
O	827	828	.

O	829	840	Venlafaxine
O	841	848	induced
O	849	853	more
O	854	858	side
O	859	866	effects
O	866	867	.

O	868	874	Median
B-outcome	875	884	reduction
I-outcome	885	887	in
I-outcome	888	890	HF
I-outcome	891	896	score
O	897	900	was
B-iv-bin-abs	901	903	49
I-iv-bin-abs	903	904	%
O	905	908	for
O	909	920	venlafaxine
O	921	924	and
B-cv-bin-abs	925	927	55
I-cv-bin-abs	927	928	%
O	929	932	for
O	933	942	clonidine
O	943	944	(
O	944	946	ns
O	946	947	)
O	947	948	.

O	949	960	Venlafaxine
O	961	964	and
O	965	974	clonidine
O	975	978	are
O	979	986	equally
O	986	987	,
O	988	991	but
O	992	1002	moderately
O	1003	1012	effective
O	1013	1015	in
B-outcome	1016	1018	HF
I-outcome	1019	1028	reduction
O	1028	1029	.

O	1030	1034	Side
O	1035	1042	effects
O	1043	1046	are
O	1047	1050	the
O	1051	1055	main
O	1056	1062	reason
O	1063	1066	for
O	1067	1071	drug
O	1072	1087	discontinuation
O	1087	1088	,
O	1089	1098	occurring
O	1099	1103	more
O	1104	1109	often
O	1110	1114	with
O	1115	1126	venlafaxine
O	1126	1127	.
